Price History
Jagsonpal Pharmaceuticals has announced the completion of a share buyback from May 8-14, 2026, purchasing two equity shares. The company has now published an advertisement about the buyback, informing both BSE and the public.
Jagsonpal Pharma saw a notable 2.66% increase in its shares, surpassing the Sensex's 1.25% growth from May 4-8, 2026. Despite mixed financial results and evaluation metrics, analysts have upgraded their cautious investment rating for the company.
Foreign institutional investors (FIIs) have shown increased interest in the Indian pharmaceutical sector, as evidenced by their growth in stakes for companies like Shilpa Medicare, Marksans Pharma, and Jagsonpal Pharma during Q1 FY26. Notably, Shilpa Medicare is expanding its presence in Latin America, Marksans Pharma has secured FDA approvals, while Jagsonpal Pharma focuses on women's health and maintaining financial discipline.
Jagsonpal Pharmaceuticals has announced a share buyback plan worth Rs. 40 crore at Rs. 250 per share, starting on May 8, 2026. This buyback will involve the acquisition of 16 lakh shares, equating to 2.38% of their equity capital.
Jagsonpal Pharma reported a significant 28% increase in Q4 EBITDA, reaching ₹111M compared to ₹87M last year. The company's margins also expanded, now standing at 17.3%, up from 14.9% in the same period last year.
Jagsonpal Pharma's Q4 profit increased by 33.1% year-on-year but dropped 20% quarter-on-quarter to ₹8.8 crore. The revenue also decreased by 12% quarter-on-quarter to ₹64.2 crore, leaving the stock at a level 31.4% below its 52-week high of ₹207.
Jagsonpal Pharma has authorized a share buyback worth INR 40 crores at INR 250 per share, intended to optimize capital and enhance shareholder value.